In addition to threonine auxotrophy, mutation of the Saccharomyces cerevisiae threonine biosynthetic genes THR1 (encoding homoserine kinase) and THR4 (encoding threonine synthase) results in a plethora of other phenotypes. We investigated the basis for these other phenotypes and found that they are dependent on the toxic biosynthetic intermediate homoserine. Moreover, homoserine is also toxic for Candida albicans thr1⌬ mutants. Since increasing levels of threonine, but not other amino acids, overcome the homoserine toxicity of thr1⌬ mutants, homoserine may act as a toxic threonine analog. Homoserine-mediated lethality of thr1⌬ mutants is blocked by cycloheximide, consistent with a role for protein synthesis in this lethality. We identified various proteasome and ubiquitin pathway components that either when mutated or present in high copy numbers suppressed the thr1⌬ mutant homoserine toxicity. Since the doa4⌬ and proteasome mutants identified have reduced ubiquitin-and/or proteasome-mediated proteolysis, the degradation of a particular protein or subset of proteins likely contributes to homoserine toxicity.
In addition to threonine auxotrophy, mutation of the Saccharomyces cerevisiae threonine biosynthetic genes THR1 (encoding homoserine kinase) and THR4 (encoding threonine synthase) results in a plethora of other phenotypes. We investigated the basis for these other phenotypes and found that they are dependent on the toxic biosynthetic intermediate homoserine. Moreover, homoserine is also toxic for Candida albicans thr1⌬ mutants. Since increasing levels of threonine, but not other amino acids, overcome the homoserine toxicity of thr1⌬ mutants, homoserine may act as a toxic threonine analog. Homoserine-mediated lethality of thr1⌬ mutants is blocked by cycloheximide, consistent with a role for protein synthesis in this lethality. We identified various proteasome and ubiquitin pathway components that either when mutated or present in high copy numbers suppressed the thr1⌬ mutant homoserine toxicity. Since the doa4⌬ and proteasome mutants identified have reduced ubiquitin-and/or proteasome-mediated proteolysis, the degradation of a particular protein or subset of proteins likely contributes to homoserine toxicity.
The enzymatic reactions and regulation of the threonine biosynthetic pathway, which have attracted interest as a set of potential antifungal drug targets (11, (48) (49) (50) , have been studied extensively in the yeast Saccharomyces cerevisiae (46) . Yeast synthesizes threonine from aspartate in five enzymatic steps via the intermediate homoserine, which is also required for methionine synthesis ( Fig. 1 ) (reviewed in reference 46) . Homoserine is converted to threonine by the sequential actions of homoserine kinase (Thr1p) and threonine synthase (Thr4p). The threonine pathway is regulated at various steps. A majority of the pathway genes are regulated at the transcriptional level by general control in response to amino acid starvation (34, 64) . The pathway is also regulated at the level of enzyme activity, most critically by threonine feedback inhibition of aspartate kinase (Hom3p), the initial step of the pathway (56, 73) , which requires an interaction between Hom3p and the FPR1-encoded FK506-binding protein, FKBP12 (1) .
In addition to threonine auxotrophy, a number of phenotypes have been observed in homoserine kinase (thr1) and/or threonine synthase (thr4) mutants, including being petite negative (10) and having sensitivity to cold (78) , UV radiation (5, 6) , ionizing radiation, cisplatin, hydrogen peroxide (5), pH 8 (21) , caffeine, sodium chloride, manganese chloride, calcium chloride (7) , and HSP90 inhibitors (57, 97) , and showing synthetic lethality with hsp82⌬ (68) , as well as defects in sporulation (9, 14) and fluid-phase endocytosis (7) . In this study, we also identified thr1⌬ and thr4⌬ mutants as being sensitive to high temperatures and, in the accompanying study, as starvation-cidal (49) . We investigated the cause of these non-threonine auxotrophic phenotypes of thr1 and thr4 mutants by comparing phenotypes of various single-and double-threonine pathway mutants and determined that these phenotypes are the consequence of toxic intermediate accumulation. We present evidence that the toxic intermediate is homoserine, which acts as a threonine analog, and test different theories to explain homoserine toxicity. Our results demonstrate a role for the ubiquitin pathway and proteasome in homoserine toxicity.
MATERIALS AND METHODS
Strains, plasmids, media, and growth conditions. The S. cerevisiae strains used in this study are isogenic with the HO strains YJM145 (58) and Y55 (60) or the ho S288c (63) background, as noted; Candida albicans strains are isogenic with SC5314 (23) . All yeast strains and plasmids used in this study are listed in Table  S1 in the supplemental material. Escherichia coli strains consisted of DH10B (Gibco BRL) and POP2136 (K-12 background; New England Biolabs). Standard bacterial and yeast culture media included Luria-Bertani (LB), yeast extractpeptone-dextrose (YPD), yeast extract-peptone-galactose (YPGal), and synthetic dextrose (SD) or SD with proline (0.1% [wt/vol]) as the nitrogen source [SD(proline)], and were prepared as described previously (83, 86) . Yeast extractpeptone-maltose [YP(maltose)] was prepared as for YPD, except that maltose (2% [wt/vol]) replaced dextrose. Where specified, medium was supplemented with L-amino acids (86), nourseothricin (Nat; 100 g ml Ϫ1 for S. cerevisiae selection and 200 g ml Ϫ1 for C. albicans selection; Hans Knöll Institute für Naturstoff-Forschung, Jena, Germany), hygromycin B (Hyg; 300 g ml
Ϫ1
; Calbiochem), or G418 (Geneticin; 200 g ml Ϫ1 [Life Technologies]). Other supplements were added as indicated in the text. S. cerevisiae and C. albicans cultures were incubated at 30°C, and E. coli cultures were incubated at 37°C, unless specified otherwise. YPD medium buffered to pH 8 contained 50 mM HEPES, and the pH was adjusted prior to autoclaving using potassium hydroxide. Salts were added to media prior to autoclaving, except calcium chloride, which was added after autoclaving.
Manipulation of DNA. DNA for PCR and Southern analyses was extracted from S. cerevisiae, C. albicans, and E. coli as described previously (36) , and plasmid DNA was isolated from E. coli using the QIAprep spin miniprep kit (Qiagen) according to the manufacturer's instructions. For Southern analysis, DNA (2 g) was digested with restriction enzyme regimes that discriminated the various wild-type (WT) and disruption genotypes, separated on a 1% (wt/vol) agarose gel, denatured, and transferred to a nylon membrane (Roche) by capillary transfer (83) . PCR-amplified hybridization probes were purified following agarose gel electrophoresis using the QIAquick gel extraction kit (Qiagen) and labeled with [␣- 32 P]dCTP (Perkin-Elmer) using the RediprimeII random prime labeling system (Amersham Biosciences), according to the manufacturer's instructions. Prehybridizations and hybridizations were carried out in ULTRAhyb buffer (Ambion), and membranes were washed as recommended by the manufacturer. Hybridized bands were visualized using a Typhoon 9200 variable mode imager (Molecular Dynamics).
All primers used in this study are listed in Table S2 in the supplemental material. All sequencing was performed by the Duke University Cancer Center Sequencing Facility.
Gene deletion and strain and plasmid construction. To disrupt genes in C. albicans, strains were transformed by electroporation with the SAT1 flipper PCR product, amplified from the plasmid pSFS2A (77) using primers that contained at their 5Ј termini 60 bp of sequence homologous to sequence flanking the gene of interest. Nat-resistant transformants were purified and verified by PCR analysis. Transformants were then cultured in YP(maltose) to induce FLP-mediated excision of the SAT1 cassette, leaving an FLP recombination target (FRT). Nat-sensitive ϩ/⌬ strains then underwent a second round of transformation to disrupt the second allele. Transformants were confirmed by phenotype where available, PCR analysis, and Southern hybridization analysis.
S. cerevisiae gene deletions were constructed by replacing genes with natMX4, kanMX4, or hphMX4 cassettes by PCR-mediated gene deletion (25, 94) . Transformation of diploid strains resulted in heterozygous gene deletions; thus, transformants were sporulated at 30°C, tetrads were dissected, and drug-resistant segregants were selected. When two or more gene deletions were made in one strain, deletions were typically made using different drug markers, sporulated strains were crossed, and diploids were selected by acquisition of multiple drug resistance. Strains were sporulated and tetrads were dissected to obtain strains with multiple homozygous deletions. Strain construction was confirmed by phenotype, where possible, and by PCR analysis.
To create the HOM3 G1355A C1356T allele encoding feedback-resistant Hom3p with a G452D substitution (56), a strain was first constructed containing an insertion of the kanMX4 cassette within both HOM3 alleles, deleting nucleotide 1355. This strain was transformed (22) to threonine and methionine prototrophy using a mutagenic oligonucleotide that was homologous to sequences 5Ј and 3Ј of the kanMX4 insertion and containing the G1355A and C1356T substitutions. Thr ϩ Met ϩ transformants were sporulated and dissected to obtain homozygous HOM3 G1355A C1356T segregants. The presence or absence of the introduced mutation was confirmed by PCR using primers homologous at the immediate 3Ј end to the mutated sequence or wild-type sequence, respectively. In addition, the G1355A and C1356T substitutions introduced a ClaI site, which could be detected following PCR amplification of HOM3 sequence and subsequent restriction endonuclease digestion by ClaI.
To place genes under P GAL1 -regulated control, 100 bp of promoter sequence immediately upstream of the start codon of the gene of interest was replaced by DNA containing hphMX4-P GAL1 by PCR-mediated deletion. hphMX4-P GAL1 DNA was amplified from plasmid pAG107 using primers homologous to hphMX4-P GAL1 (3Ј termini) and the HOM3 promoter sequence or the start of the HOM3 open reading frame (ORF) (5Ј termini). pAG107 was constructed by replacing the kanMX6 cassette in pFA6a-kanMX6-PGAL1 (55) with an hphMX4-containing BglII-SpeI fragment from pAG32 (25) and is available from EUROSCARF (University of Frankfurt, Germany). The PCR product was introduced into yeast, and Hyg-resistant transformants were selected. Strain construction was confirmed by PCR and by galactose dependence for methionine and threonine prototrophy in homozygous hphMX4-P GAL1 HOM3 strains.
The stc1 (suppressor of thr4 cold sensitivity) mutant was isolated in the Y55 background as follows. Spores of Y55-1040 were plated onto YPD and incubated for 1 month at 5°C to select for cold sensitivity (Cs
thr4 mutant was sporulated and crossed with spores of an isogenic HO lys2 strain, which was sporulated and dissected. The resulting segregants were tested for threonine auxotrophy, cold sensitivity, and sensitivity to 0.75 M NaCl and 1.5 M KCl. The thr4 and stc1 mutations were unlinked. The stc1 mutation did not suppress the threonine auxotrophy of thr4 but did suppress the thr4 cold sensitivity and 0.75 M NaCl sensitivity phenotypes. In both thr4 and THR4 backgrounds, the stc1 mutation conferred sensitivity to 1.5 M KCl.
To identify the stc1-complementing gene in plasmid pJO304 (YCp50 backbone with genomic DNA insert cloned at the BamHI site [79] ), various deletions were made and their ability to complement stc1 was determined (see Fig. S1 in the supplemental material). To construct plasmid pJO316, pJO304 was digested with SnaBI and religated according to the ligase manufacturer's instructions (Invitrogen), resulting in a 4.86-kb deletion. Plasmid pJO317 was constructed following the digestion of pJO304 with SwaI and religation, resulting in a 7.91-kb deletion. Plasmid pJO318 contained an 8.33-kb deletion following the digestion of pJO304 with XbaI and subsequent ligation. Plasmid pJO400 contained a precise replacement of DOA4 with natMX4 following transformation of YJK1054 with a doa4⌬::natMX4 PCR targeting product.
The plasmids pJO335-pJO340 and pJO348-pJO350 were identified as highcopy suppressors of the thr1⌬ mutant homoserine toxicity and contain 5-to 10-kb insertions within the SalI restriction site on plasmid pRS426 (see Table S1 in the supplemental material). To identify the gene responsible for homoserine toxicity suppression in each plasmid, various deletions were made and the plasmid was tested for the ability to suppress the thr1⌬ homoserine toxicity (see Fig. S2 in the supplemental material). Plasmid pJO335 was digested with BamHI and HindIII individually and religated to create plasmids pJO341 and pJO342, containing 3.35-kb and 4.20-kb deletions, respectively. pJO336 was digested with HindIII and SpeI individually and religated, resulting in plasmids pJO343 and pJO344 with 0.72-kb and 4.20-kb deletions, respectively. pJO345 contained a 1.27-kb deletion following the digestion of pJO338 with SpeI and subsequent religation. pJO347 resulted from deletion of a 1.29-kb SacI fragment from pJO339. pJO401, pJO402, pJO403, and pJO404 contained a precise replacement by hphMX4 of either the entire NTR2 sequence, bp 1 to 575 of NTR2, the entire ALY1 sequence, or bp 1 to 1411 of ALY1, respectively, constructed by transformation of YJK1386 with PCR targeting constructs. All constructs were confirmed by restriction digest analysis.
The plasmids pJO364 and pJO367/pJO368, were constructed by cloning S. cerevisiae THS1 or E. coli thrRS, respectively, under the control of the TEF promoter and terminator, replacing the hph gene in pBN05, which was derived from pAG26 (hphMX4 CEN URA3) (25) by replacement of the URA3 ORF by NAT1 (available from EUROSCARF, University of Frankfurt, Germany). THS1 was amplified from strain S157 DNA, and thrRS was amplified from E. coli POP2136 (isogenic with E. coli K-12 [New England Biolabs]) using primers that were homologous at their 5Ј ends to the 3Ј region of the TEF promoter or 5Ј region of the TEF terminator. PCR products and NotI-digested pBN05 (cuts twice within hphMX4) were introduced into strain YJK738 or S94, and transformants in which the plasmid has been gap repaired (65) by the THS1 (pJO364) or thrRS (pJO367 and pJO368) PCR product or reannealed (pJO365; hph partial deletion) were selected by acquisition of Nat resistance. Hyg-sensitive plasmids were isolated, introduced into E. coli DH10B (87) for amplification, purified, and then confirmed by PCR and restriction endonuclease digestion analysis.
Sensitivity assays. For each sensitivity assay, two independent mutants containing the same gene deletion were typically tested. Sensitivity to peroxide was assayed by resuspending approximately 10 7 CFU ml Ϫ1 of cells, which had been cultured for approximately 16 h in YPD, into 3 ml YPD containing tert-butylperoxide (Sigma; 0.1% [vol/vol] ). Cultures were incubated with aeration at 30°C for 2 h, and survival was assessed following plating of 5-l volumes of 10-fold spot dilutions of aliquots, removed before and after incubation. Sensitivities to FK506 (LC Laboratories), L-homoserine (Sigma or NovaBiochem), sulfometuron methyl (SM; Chem Service), and 3-amino-1,2,4-triazole (3-AT; Sigma) were determined in triplicate using the MIC assay (MIC 80 ), as described previously (51) . FK506 and homoserine MICs were performed in YPD medium and incubated for 1 day, while SM and 3-AT MICs were performed in SD medium supplemented with threonine and methionine (SD ϩ Thr ϩ Met), and incubated for 2 days. FK506 was prepared as 10ϫ working concentrations in To test UVC sensitivity, 5-l volumes of 10-fold dilutions were spotted onto YPD plates. Plates were irradiated 200 J/m 2 with UV (254 nm) using a Stratalinker UV Cross-linker (Stratagene) and then incubated in the dark at 30°C for 2 days.
Sensitivity to sodium chloride (0.7 M), lithium chloride (0.05 M), and calcium chloride (0.25 M) at pH 8 at 41°C, 6°C, or 8°C was assayed by plating 5-l volumes from a 10-fold dilution series of cultures (starting at approximately 10 8 CFU/ml) onto the desired YPD-based medium and/or incubation at the temperature specified.
To perform threonine starvation assays, strains that had been grown overnight in YPD and washed twice in sterile water were inoculated into 5 ml SD or SD ϩ Met to a concentration of approximately 10 7 CFU ml
. Aliquots were removed at various time points, and viable counts were either estimated by plating 5-l aliquots of 10-fold spot dilutions, or 100-l aliquots of specific dilutions were plated for more precise estimates. When overall numbers were determined, experiments were performed in triplicate.
Cycloheximide suppression of homoserine toxicity. To test whether cycloheximide suppresses homoserine toxicity in thr1⌬ mutants, thr1⌬ mutants were grown overnight in minimal medium (SD) with 10ϫ regular threonine concentrations (3 mg ml
, to reduce flux through threonine pathway by feedback inhibition and hence reduce homoserine accumulation). Cells were added to SD ϩ Thr (10ϫ) medium containing 0, 0.1, 1, or 10 g ml Ϫ1 cycloheximide (approximately 1 ϫ 10 8 cells ml
) and incubated with aeration for 2 h at 30°C. Cells were pelleted, washed twice with water, and resuspended in an equivalent volume of SD ϩ Thr (0.1ϫ at 0.03 mg ml
) medium containing cycloheximide, at levels used previously. Cultures were split, and homoserine (1 mg ml
) was added to one sample of each duplicate. Cultures were incubated at 30°C with aeration, aliquots were removed at times 0, 3, 6, and 24 h following homoserine addition, and 5-l volumes of 10-fold dilutions were plated.
RESULTS

Phenotypes of threonine pathway mutants.
To determine whether thr1 and thr4 mutant phenotypes are caused by (i) threonine auxotrophy, (ii) THR1 and/or THR4 encoding an activity additional to threonine biosynthesis, or (iii) the accumulation of a toxic intermediate caused by pathway blockage, the phenotypes of threonine (and methionine) biosynthetic mutants were compared for various conditions reported to be inhibitory to thr1 and/or thr4 mutants (5-7, 21, 49, 78) , as well as a variety of other phenotypes described below.
Unless specified otherwise, experiments were performed in the YJM145 background. In this background, thr1⌬ (YJK498a and YJK506a) and thr4⌬ (YJK369b and YJK391b) mutants were not sensitive to CaCl 2 (0.25 M), and thr1⌬ mutants were not petite negative, since mip1⌬ thr1⌬ segregants from sporulated and dissected MIP1/mip1⌬ THR1/thr1⌬ strains were viable. However, thr1⌬ mutants were more sensitive than the wild-type (YAG129), met2⌬ (YJK561 and YJK565), and hom3⌬ (YJK487a and YJK495a) mutants to sodium chloride (0.7 M), lithium chloride (0.05 M), pH 8, incubation at 41°C and 6°C, threonine starvation, tert-butylperoxide, caffeine, and UVC ( Table 1 ). The thr1⌬ mutants were also more sensitive than hom6⌬ (YJK862 and YJK865) mutants to pH 8, 41°C, UVC, lithium chloride, and threonine starvation. Similarly, thr4⌬ mutants were sensitive to each condition that inhibited thr1⌬ mutants, although to a lesser degree in some instances. Therefore, since the thr1⌬ and thr4⌬ mutant phenotypes differ from those observed for hom3⌬ and hom6⌬ mutants, these phenotypes are not due to threonine auxotrophy alone.
To determine whether phenotypes result from Thr1p and Thr4p having an additional, non-threonine biosynthetic role or from toxic intermediate accumulation caused by pathway blockage, hom3⌬ thr1⌬ (YJK671 and YJK682), hom3⌬ thr4⌬ (YJK677 and YJK680), hom6⌬ thr1⌬ (YJK939 and YJK948), and hom6⌬ thr4⌬ (YJK1380 and YJK1381) double mutants were constructed, and their phenotypes were compared with those of single mutants. For every phenotype tested, the phenotypes of the hom3⌬ thr or hom6⌬ thr double mutants were identical to the phenotypes of single hom3⌬ or hom6⌬ mutants, respectively (Table 1) . Therefore, since the hom3⌬ and hom6⌬ mutations suppressed thr1⌬ and thr4⌬ phenotypes, the deleterious phenotypes of thr1⌬ and thr4⌬ mutants are likely caused by the accumulation of a toxic intermediate, such as homoserine (Fig. 1) .
Exogenous homoserine is toxic to thr1⌬ and thr4⌬ mutants. If endogenously produced homoserine is toxic, with the homoserine metabolizing enzymes acting as major (Thr1p and Thr4p) and minor (Met2p) homoserine detoxification pathways ( Fig. 1 ), then exogenous homoserine should be toxic to thr1⌬ and thr4⌬ mutants. While no inhibition of hom3⌬, hom6⌬, met2⌬, or wild-type strains by homoserine was observed on YPD plates (1 mg ml Ϫ1 homoserine; Fig. 2 ) or YPD broth (MIC 80 , Ͼ2 mg ml Ϫ1 ), consistent with homoserine being toxic unless detoxified by conversion into threonine, thr1⌬, thr4⌬, and thr1⌬ met2⌬ strains were extremely sensitive to exogenous homoserine ( Fig. 2; MIC 80 , 0.125 mg ml Ϫ1 ). Although hom6⌬ thr1⌬ and hom6⌬ thr4⌬ strains were unable to 
VOL. 9, 2010 HOMOSERINE TOXICITY 719 synthesize homoserine or metabolize homoserine to threonine, strains were as homoserine sensitive as thr1⌬ and thr4⌬ strains (MIC 80 , 0.125 mg ml Ϫ1 ), presumably due to the combined effect of exogenous homoserine and toxic ␤-aspartate semialdehyde, which accumulates in hom6⌬ mutants (4) . The hom3⌬ thr1⌬ and hom3⌬ thr4⌬ strains, which are unable to synthesize homoserine endogenously or metabolize homoserine to threonine and do not accumulate other toxic intermediates, had a reduced sensitivity to exogenous homoserine ( Fig. 2; MIC 80 , 0.25 mg ml Ϫ1 ) compared with thr1⌬ and thr4⌬ strains. Influence of pathway flux on thr1⌬ phenotype. If endogenously produced homoserine is responsible for the deleterious thr1⌬ mutant phenotypes, increasing threonine biosynthetic pathway flux should increase homoserine accumulation and consequently exacerbate the deleterious phenotypes of thr1⌬ mutants. Growth of thr1⌬ mutants was therefore observed following five approaches that increase the threonine pathway flux. For the first approach, since starvation for amino acids induces transcription of threonine pathway genes via the general control pathway (34, 64) , administration of the general control-eliciting drugs SM (which inhibits Ilv2p) (15, 45) and 3-AT (which inhibits His3p) (2, 85, 95) should increase flux through the threonine biosynthetic pathway. We therefore determined the MIC 80 levels of SM and 3-AT for threonine pathway mutants. The thr1⌬ mutants were found to be four times more sensitive to SM than the wild type or hom3⌬ and hom3⌬ thr1⌬ mutants ( Table 2 ). The thr1⌬ mutants were more than 10-fold more sensitive to 3-AT than the hom3⌬ and hom3⌬ thr1⌬ mutants and a striking ϳ100-fold times more sensitive than the wild type. Since thr1⌬ mutants are sensitive to general control elicitors, and the sensitivity is suppressed to the levels observed in hom3⌬ mutants in hom3⌬ thr1⌬ mutants, results are consistent with the hypersensitivity being a consequence of toxic intermediate accumulation.
Mutations in HOM3 that abolish the threonine-mediated feedback regulation of aspartate kinase (Hom3p) result in overproduction of threonine and homoserine (16, 17, 56, 73, 74) . A diploid strain was constructed that was heterozygous for a feedback-resistant (FBR) HOM3 allele and THR1 deletion (YJK1595; HOM3 FBR /hom3::kanMX4 THR1/thr1⌬::natMX4). The strain was sporulated, tetrads were dissected, and resulting viable colonies were replica plated to YPD ϩ Nat and YPD ϩ G418 media to determine spore genotypes. In 45 tetrads dissected, all thr1⌬ HOM3 FBR segregants were inviable (Fig. 3A) . Therefore, thr1⌬ is synthetic lethal with HOM3 FBR . Since an interaction between Hom3p and FKBP12 (encoded by FPR1) is required for feedback regulation of the threonine pathway, disruption of FPR1 results in increased pathway flux (1) . Consistent with the effect of fpr1⌬ on pathway flux, following the sporulation and dissection of 82 tetrads of THR1/ thr1⌬ FPR1/fpr1⌬ strains (YJK1792 and YJK1793; Fig. 3B ), no thr1⌬ fpr1⌬ segregants were recovered. Therefore, thr1⌬ is also synthetically lethal with fpr1⌬.
HOM3 and HOM3 FBR were also placed under the control of the GAL1 promoter (P GAL1 HOM3 and P GAL1 HOM3 FBR ) in both thr1⌬ and thr1⌬ met2⌬ backgrounds, and growth was compared on media with either dextrose (YPD, P GAL1 OFF) or galactose (YPGal, P GAL1 ON) as the carbon source. Strains grew as well as the wild type on YPD, but were severely inhibited compared with the wild-type on YPGal (Fig. 3C) . The degree of growth inhibition for strains corresponded with the predicted levels of homoserine accumulated by each strain: THR1 MET2 (no inhibition) Ͼ P GAL1 HOM3 thr1⌬ Ͼ P GAL1 HOM3 thr1⌬ met2⌬ Ն P GAL1 HOM3 FBR thr1⌬ Ͼ P GAL1 HOM3 FBR thr1⌬ met2⌬ (no growth).
Finally, since the Hom3p-FKBP12 interaction is blocked by the immunosuppressant drug FK506 (1), we tested the FK506 sensitivity of strains. Consistent with Hillenmeyer et al. (33) , thr1⌬ mutants (YJK498a and YJK506a) were found to be more sensitive than the wild-type (YAG129), hom3⌬ (YJK487a), and hom3⌬ thr1⌬ (YJK671) strains to FK506 in a MIC assay at 37°C. Specifically, MIC 80 values were Ͼ100 g ml Ϫ1 for wildtype, hom3⌬, and hom3⌬ thr1⌬ strains, compared with 12.5 to 25 g ml Ϫ1 for thr1⌬ strains (Table 2) . Taken together, these results demonstrate increased toxicity to thr1⌬ strains as a consequence of increasing the flux through the threonine bio- Homoserine is also toxic for C. albicans thr1⌬ mutants. To investigate whether homoserine accumulation is also toxic in C. albicans, we first tested if C. albicans thr1⌬ mutants were sensitive to exogenous homoserine. Like S. cerevisiae thr1⌬ mutants, growth of C. albicans thr1⌬ (CJK35) and thr1⌬ met2⌬ (CJK100) mutants was completely inhibited by exogenous homoserine (1 mg ml Ϫ1 ) in YPD plates, while growth of the wild type (SC5314) and hom3⌬ and met2⌬ mutants was unaffected (Fig. 2) . Growth inhibition of the thr1⌬ mutant by exogenous homoserine was partially suppressed by disruption of HOM3, which eliminates endogenous biosynthesis of homoserine (MIC 80 , 1 mg ml Ϫ1 ). Furthermore, consistent with S. cerevisiae results, homoserine MIC 80 assays showed that the thr1⌬ met2⌬ mutant was more homoserine sensitive than the thr1⌬ mutant, with MIC 80 s of 0.125 mg ml Ϫ1 and 0.5 mg ml Ϫ1 , respectively. Therefore, homoserine is also toxic in C. albicans thr1⌬ mutants.
We next investigated whether mechanisms that increase the flux through the C. albicans threonine biosynthetic pathway are deleterious for C. albicans thr1⌬ mutants. Since general control has been demonstrated in C. albicans (69, 92) , the SM and 3-AT MIC 80 values were determined for C. albicans strains. As seen in Table 2 , although C. albicans thr1⌬ mutants were no more sensitive to 3-AT than the wild type, the thr1⌬ mutants were 32 times more sensitive to SM than the wild type and 8 times more sensitive than the hom3⌬ and hom3⌬ thr1⌬ strains. Therefore, as with S. cerevisiae, the SM hypersensitivity of C. albicans thr1⌬ mutants is consistent with toxic intermediate accumulation.
The mechanism of C. albicans Hom3p feedback regulation differs from that of S. cerevisiae. We tested the effect of FKBP12 and FK506, which regulate threonine feedback inhibition of S. cerevisiae Hom3p (1), on C. albicans thr1⌬ mutants. The C. albicans homolog of S. cerevisiae Fpr1p/FKBP12, with which it shares 56% amino acid identity, is Rbp1p. To determine if the mechanism of feedback regulation of C. albicans Hom3p functions in the same manner as in S. cerevisiae, we attempted to construct a thr1⌬ rbp1⌬ mutant. Interestingly, in contrast to the S. cerevisiae thr1⌬ fpr1⌬ mutant synthetic lethality, the C. albicans thr1⌬ rbp1⌬ mutant (CJK106) was viable and only modestly (2-fold) more sensitive than the thr1⌬ mutant to homoserine in a MIC 80 assay (MIC 80 values were 0.25 and 0.5 mg ml Ϫ1 homoserine, respectively, after 1 day of incubation in YPD at 30°C). Consistent with this, we determined that C. albicans thr1⌬ mutants were not hypersensitive to FK506 following incubation at 30°C or 37°C for 1 day; the MIC 80 values for all strains were Ͼ100 g ml Ϫ1 ( Table 2 ). The lack of an effect of administration of FK506 and little effect of disruption of RBP1 on C. albicans thr1⌬ mutants suggest that either the C. albicans threonine pathway flux is controlled by a Hom3p feedback-independent mechanism, such as phosphatase degradation of aspartyl phosphate, or the threonine feedback mechanism of C. albicans Hom3p differs from that of S. cerevisiae in that it does not involve Rbp1p.
Does homoserine act as a serine or threonine analog? Since homoserine is structurally similar to serine and threonine, one model to explain the homoserine toxicity is that homoserine 
Strains included YJK1012 (P GAL1 -HOM3 thr1), YJK1010 (P GAL1 -HOM3 thr1 met2), YJK1007 (P GAL1 -HOM3
FBR thr1), and YJK1004 (P GAL1 -HOM3 FBR thr1 met2).
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on November 3, 2017 by guest http://ec.asm.org/ may act as an analog, either inhibiting or being metabolized by a reaction normally utilizing threonine or serine as a substrate. If homoserine is acting as a threonine or serine analog, increasing levels of exogenous threonine or serine should counteract the homoserine toxicity. We therefore compared the growth rates of the P GAL1 -HOM3 and P GAL1 -HOM3 FBR thr1⌬ and/or met2⌬ homoserine-accumulating strains (YJK1004, YJK1007, YJK1010, and YJK1012) on YPGal plates containing a filter disc to which 50 l of the following amino acids had been added individually: leucine (10 mg ml Ϫ1 ), lysine (15 mg ml Ϫ1 ), histidine (20 mg ml Ϫ1 ), methionine (20 mg ml Ϫ1 ), glycine (60 mg ml Ϫ1 ), isoleucine (6 mg ml Ϫ1 ), valine (30 mg ml Ϫ1 ), tryptophan (10 mg ml Ϫ1 ), D,L-homocysteine (10 mg ml Ϫ1 ), serine (60 mg ml Ϫ1 ), or threonine (60 mg ml Ϫ1 ). The only amino acids in which elevated levels affected growth were serine, which further inhibited growth, possibly by competing for threonine uptake, and threonine, which substantially enhanced growth (Fig. 4) . To eliminate the possibility that threonine suppression of homoserine-mediated inhibition was due to uptake of threonine competing with reuptake of homoserine that may have been excreted, the growth of homoserine-accumulating strains was also compared when 50 l of the dipeptides Ala-Thr or Thr-Ala (50 mg ml Ϫ1 ) was added, and similar suppression was observed. Since the suppression by threonine was observed in strains in which HOM3 expression was regulated by P GAL1 and not general control and that were resistant to Hom3p feedback inhibition, the threonine suppression of toxicity was not due to a reduction in flux through the threonine pathway. Instead, since both threonine and the threoninecontaining dipeptides overcame the growth suppression caused by homoserine, the results are consistent with homoserine acting as a toxic threonine analog.
If homoserine toxicity is caused by inhibition of a reaction that utilizes threonine as a substrate, disruption of the gene whose product is inhibited by homoserine would result in the same phenotypes in a THR1 background as those associated with homoserine accumulation in a thr1⌬ background. Therefore, to test this hypothesis, we disrupted three genes whose products metabolize threonine (CHA1, ILV1, and GLY1) in a THR1 background and compared homoserine accumulationassociated phenotypes (sensitivity to 41°C, 8°C, NaCl, LiCl, and pH 8). While several single gene deletions resulted in some of the same phenotypes as thr1⌬ mutants, none of the mutants was sensitive to all conditions (Table 3) . Thus, homoserine is likely not acting as an inhibitor of Cha1p, Ilv1p, or Gly1p.
If homoserine toxicity is mediated by its metabolism in a reaction for which threonine is a substrate, disruption of the gene whose product is metabolizing homoserine would suppress the homoserine toxicity and phenotypes associated with homoserine accumulation of thr1⌬ mutants. However, we find that the cha1⌬ mutation did not suppress the thr1⌬ homoserine toxicity or any of the homoserine accumulation-dependent phenotypes. The phenotypes of the gly1⌬ thr1⌬ and ilv1⌬ thr1⌬ strains could not be tested due to synthetic lethality, which was suppressed by hom3⌬, consistent with gly1⌬ and ilv1⌬ increasing threonine biosynthetic pathway flux by general control. However, hom3⌬ gly1⌬ thr1⌬ and hom3⌬ ilv1⌬ thr1⌬ strains were as sensitive to exogenous homoserine as a hom3⌬   FIG. 4 . Serine suppresses, while threonine enhances growth in homoserine-overproducing strains. Strains were applied to YPGal plates, threonine or serine (50 l of 60 mg ml Ϫ1 ) was added to a central filter disc, and plates were incubated at 37°C for 2 days. Strains included YAG129 (HOM3 THR1), YJK1012 (P GAL1 -HOM3 thr1), YJK1010 (P GAL1 -HOM3 thr1 met2), YJK1007 (P GAL1 -HOM3 FBR thr1), and YJK1004 (P GAL1 -HOM3 FBR thr1 met2). 
thr1⌬ strain. Therefore, homoserine toxicity is also not caused by its metabolism by Cha1p, Gly1p, or Ilv1p.
Does homoserine inhibit or replace threonine incorporation in translation?
The final process using threonine as a substrate involves translation. If homoserine inhibits the threonyl-tRNA synthetase Ths1p, overexpression of THS1 should alleviate thr1⌬ homoserine toxicity. The homoserine sensitivity of the S. cerevisiae YJM145 background strains YJK1301, YJK1302 (P GAL1 THS1/THS1), YJK1319, and YJK1321 (P GAL1 THS1/ THS1 thr1⌬/thr1⌬), were compared in P GAL1 inducing and repressing conditions. In addition, the homoserine sensitivity of S288c background strains YJK726 (thr1⌬), YJK2380 (thr1⌬ P GAL1 THS1), and YJK2376 [thr1⌬ P GAL1 THS1 plus pJO364 (CEN THS1MX4)] were compared under inducing conditions. In all cases, overexpression of THS1 had no influence on homoserine toxicity of thr1⌬ mutants: thus, homoserine likely does not inhibit Ths1p.
The toxic effects of homoserine may be due to its misincorporation into proteins in the place of threonine, via mis-acylation by the threonyl-tRNA synthetase, Ths1p. Since the E. coli threonyl-tRNA synthetase, encoded by thrRS, does not mis-acylate homoserine (30) , to test if homoserine toxicity is due to aminoacylation by S. cerevisiae Ths1p, we investigated whether the homoserine toxicity of S. cerevisiae thr1⌬ mutants could be suppressed by expression of the E. coli thrRS instead of THS1. First, we tested the functionality of the thrRS gene product in S. cerevisiae. The growth rates of S288c background thr1⌬ P GAL1 -THS1 strains containing low-copy-number plasmids expressing hph (pJO365 in control strain YJK2403), THS1 (pJO364 in strain YJK2376), or thrRS (pJO367 and pJO368 in strains YJK2405 and YJK2412, respectively) from the constitutive TEF promoter were compared on YPD and YPGal. The thr1⌬ P GAL1 -THS1 control strain (YJK2403) did not grow on YPD; therefore, P GAL1 -THS1 is indeed not expressed in YPD. Since strains containing the thrRS-expressing plasmids grew on YPD (i.e., chromosomal P GAL1 -THS1 OFF), E. coli thrRS encodes a functional threonyl-tRNA synthetase in S. cerevisiae. The homoserine MIC 80 values were then compared in both YPD and YPGal. We found no difference between the homoserine sensitivity of thr1⌬ P GAL -THS1 strains expressing plasmid-borne THS1 versus thrRS in YPD (MIC 80 values were 500 g ml Ϫ1 ) or YPGal (MIC 80 values of 1,000 g ml Ϫ1 ). Therefore, our results indicate that the toxic effects of homoserine do not involve, or do not solely involve, mis-acylation by the threonyl-tRNA synthetase Ths1p.
If homoserine toxicity is due to its incorporation into proteins in place of threonine, treatment with the translation inhibitor cycloheximide should suppress the homoserine toxicity of thr1⌬ mutants. To test this hypothesis, a thr1⌬ strain, YJK498a, was first incubated for 2 h in SD ϩ Thr (10ϫ, 3 mg ml Ϫ1 ) with various amounts of cycloheximide (0 to 10 g ml Ϫ1 ) and in the absence of exogenous homoserine, over which time, thr1⌬ mutant cell viability was unchanged from initial levels for all samples (Fig. 5 ). Cells were then transferred to SD ϩ Thr (0.1ϫ at 0.03 mg ml Ϫ1 ) containing the same cycloheximide concentrations as the preincubation step, cultures were split, and homoserine was added to half of the samples. Following 3 h of incubation, while all other samples remained at input levels, there was an approximate 10,000-fold reduction in thr1⌬ mutant levels in the sample containing homoserine without cycloheximide. Similarly, following 6 h of incubation, there was a 10,000-fold reduction in thr1⌬ mutant levels in the sample without homoserine or cycloheximide (probably reflecting starvation following threonine depletion from medium), as well as a further decline in levels for the sample containing homoserine without cycloheximide. However, the presence of cycloheximide blocked killing in all samples, with increasing protection correlating with increasing levels of cycloheximide. The results indicate a requirement for protein synthesis for homoserine toxicity, consistent with homoserine toxicity being caused by its incorporation into proteins.
Identification of high-copy suppressors of the homoserine toxicity. To better understand homoserine toxicity, we isolated high-copy suppressors of thr1⌬ mutant homoserine toxicity. Strain YJK928 (thr1⌬ ura3⌬) was transformed with a URA3-marked 2m high-copy-number yeast genomic library containing 5-to 10-kb insertions within the SalI restriction site on plasmid pRS426 (constructed by C. Alarcon). Ura ϩ transformants were selected, replica plated to YPD ϩ homoserine (1 mg ml Ϫ1 ), and homoserine-resistant transformants were screened for threonine prototrophy to eliminate clones containing the THR1 gene. Plasmids were isolated from threonine-auxotrophic, homoserine-resistant transformants and reintroduced into naïve YJK928 to confirm the plasmid dependence of the homoserine-resistant phenotype. From a total of approximately 30,000 transformants screened, we isolated eight plasmids belonging to five different complementation groups. Following subcloning, and ruling out genes designated by the Saccharomyces Genome Database (www.yeastgenome.org) as dubious ORFs, we determined that the suppressing genes were S2 in the supplemental material). Although we observed reduced suppression by disruption of NTR2 in pJO335, we attribute this to an effect on ALY1 expression (only 190 bp separates the 3Ј terminus of ALY1 from the 3Ј end of NTR2) since disruption of ALY1 completely eliminated homoserine resistance. Plasmids suppressed the homoserine toxicity at different levels, with the approximate order of suppression comprising pJO335 (ALY1) Ն pJO338 (HUA1) Ͼ pJO336 (SNA3) Ͼ pJO340 (TAT1) Ͼ pJO339 (SSH4) (Fig. 6A) . Besides the tryptophan and tyrosine permease gene TAT1 (84) , all other suppressor genes isolated are associated with the ubiquitin pathway (29, 47, 52-54, 76, 88) . Synthetic pma1-114 doa4, thr1⌬ pma1-114 and thr1⌬ doa4 phenotypes. In the S. cerevisiae Y55 background, a mutation designated stc1 was isolated that suppressed thr4 cold sensitivity and partially suppressed the homoserine toxicity of thr4-1 mutants (Materials and Methods). Interestingly, we find that the stc1, thr4, and thr1⌬ mutations all have synthetic phenotypes in combination with a mutant allele of the plasma membrane Pma1p H ϩ -ATPase gene, pma1-114 (61), which results in depolarization of cellular membrane potential (71) . Compared with thr4, thr1⌬, or pma1-114 mutants, thr4 pma1-114 and thr1⌬ pma1-114 strains were hypersensitive to growth on YPD ϩ KCl (1.5 M) or glycerol (2.5 M), and these phenotypes were homoserine dependent, since sensitivity was suppressed by hom3⌬ (data not shown). Furthermore, relative to pma1-114 strains and stc1 strains, pma1-114 stc1 strains were more temperature sensitive at 37°C and sensitive to growth on YPD ϩ 1.5 M KCl, a phenotype that we exploited to identify STC1.
To clone STC1, we introduced a wild-type yeast genomic library containing 15-to 20-kb genomic inserts housed in a YCp50 URA3-marked centromeric vector (79) into an stc1 pma1-114 strain (YJK1018) and screened for complementation of the KCl sensitivity. From approximately 25,000 transformants, two KCl-resistant transformants were isolated; following restriction digest analysis, both plasmids were determined to contain identical 15.2-kb inserts (pJO304). The complementing plasmid conferred KCl and high-temperature resistance when introduced into a naïve stc1 pma1-114 strain. By deleting various regions of the complementing plasmid, the complementing gene was determined to be DOA4 (see Fig. S1 in the supplemental material). Furthermore, a doa4⌬ pma1-114 strain (YJK1060) exhibited the same KCl and temperature sensitivity observed for stc1 pma1-114 strains. Finally, doa4⌬ disruption in the YJM145 background thr1⌬ strain (YJK1077) partially suppressed the thr1⌬-dependent NaCl and homoserine sensitivity (Fig. 6A ). DOA4 encodes a ubiquitin isopeptidase that is important for recycling ubiquitin from proteasome-bound ubiquitinated intermediates (90) . The synthetic doa4⌬ pma1-114 phenotype is consistent with previous findings that the fate and sorting of another mutant Pma1p protein are regulated by ubiquitination (26, 72) . Importantly, the suppression of thr1⌬ phenotypes by doa4⌬ further implicates the ubiquitin pathway in mediating the thr1⌬ mutant homoserine toxicity.
To investigate whether doa4⌬ may suppress thr1⌬ phenotypes by mechanisms distinct from enhanced stability of various amino acid permeases (18, 27 ) that might increase threonine uptake, we studied the effect of doa4⌬ on thr1⌬ starvation in SD. Interestingly, while the viability of a thr1⌬ strain (YJK498a) was reduced on average 66-fold after 4 h of starvation and 479-fold after 8 h of starvation, an isogenic doa4⌬ thr1⌬ strain (YJK1077) remained at approximately input levels after 8 h, with a reduction in viability of only 1.5-fold (Fig. 6B) . Therefore, while increased amino acid import may play a role in the doa4⌬ suppression of thr1⌬ phenotypes, suppression also occurs by an alternative mechanism.
Role for proteasome function in homoserine toxicity. The doa4⌬ suppression of thr1⌬ phenotypes suggests that reduction of ubiquitin-mediated turnover of a protein, a subset of proteins, or all proteins benefits thr1⌬ survival. Since ubiquitinated proteins may be degraded by the proteasome, we investigated a role for the proteasome in thr1⌬ toxic phenotypes. The ATPases encoded by RPT6 (CRL3) and RPT4 (CRL13), and a proteolytic enzyme encoded by PRE3 (CRL21) comprise three subunits of the proteasome (24, 28, 37, 80, 82) , all three of which are required for maximal proteasome-dependent proteolysis (20, 81) .
First, we investigated the effect of reduced proteasome function on the homoserine sensitivity of thr1⌬ mutants, using the Y55 background-the background in which the crl (cycloheximide-resistant, ts-lethal) mutants were isolated and described (59, 60) . Experiments with the crl strains were performed at the semipermissive temperature of 30°C. Significantly, thr1⌬ strains containing the crl3-3 (YJK2596 and YJK2598), crl13-1 (YJK2619 and YJK2620), or crl21-1 (YJK2613 and YJK2618) alleles were resistant to 4-fold-higher levels of homoserine (MIC 80 of 0.5 mg ml Ϫ1 ) than a thr1⌬ strain with wild-type proteasome function (YJK1766; MIC 80 of 0.125 mg ml Ϫ1 ). We also compared the effect of the crl alleles on the thr1⌬ starvation phenotype. Since crl mutants have been described as exhibiting an incorrect amino acid starvation response (59), we first compared the effects of reduced proteasome function on homoserine-independent threonine starvation, using a hom3⌬ background. The hom3⌬ crl3-3 (YJK2599), hom3⌬ crl13-1 (YJK2590), and hom3⌬ crl21-1 (YJK2614) strains survived threonine starvation (SD ϩ Met) 3.9-, 1.9-, and 1.3-fold less well after 24 h, respectively, than a hom3⌬ strain (YJK2591) (Fig. 7) , consistent with various degrees of defective starvation response in the crl backgrounds. Despite this defect, all crl mutations were found to significantly suppress the threonine starvation-cidal defect of thr1⌬ mutants at all time points assayed (Fig. 7) . Specifically, compared with a thr1⌬ strain (YJK1766), the average increased viability after 4, 8, and 24 h, respectively, included 107-, 118-, and 29-fold for crl3-3 thr1⌬ strains (YJK2596 and YJK2598); 130-, 945-, and 451-fold for crl13-1 thr1⌬ strains (YJK2619 and YJK2620); and 191-, 1,383-, and 1,056-fold for crl21-1 thr1⌬ strains (YJK2613 and YJK2618). Therefore, reduction of proteasome-mediated proteolysis suppresses homoserine toxicity.
DISCUSSION
Myriad phenotypes not typically associated with amino acid auxotrophy, such as sensitivity to pH (21) , salts (7), cold (78) DNA-damaging agents (5, 6) , and threonine starvation (49) have been described for S. cerevisiae thr1 and thr4 mutants. Here, we report that these mutants are also sensitive to high temperatures, as well as KCl and glycerol when combined with the pma1-114 allele. We dissected the basis of these phenotypes and determined that rather than being due to a general consequence of threonine auxotrophy or the loss of a secondary function of these enzymes, the phenotypes are caused by the toxic intermediate homoserine. Homoserine was also toxic for C. albicans thr1⌬ mutants. Our findings are consistent with the growth impairment previously observed in homoserineoverproducing yeast, which was attributed to substantial restructuring of the metabolic flux or accumulation of metabolites, such as threonine or homoserine, interfering with general cell metabolism (16) . Our results are also consistent with homoserine toxicity in mammalian cells, which is suppressed by coexpression of bacterial homoserine kinase and threonine synthase, which simultaneously synthesize threonine and detoxify homoserine (75) .
In S. cerevisiae, threonine feedback regulation is mediated by an interaction between aspartate kinase and the FPR1 gene product, FKBP12, which is inhibited by FK506 binding FKBP12, resulting in increased flux through the pathway (1). Consistent with this, S. cerevisiae thr1⌬ mutation was synthetic lethal in combination with fpr1⌬, and thr1⌬ mutants were hypersensitive to FK506. Interestingly, however, we found no observable phenotype upon disruption of the orthologous gene in C. albicans, RBP1, in combination with thr1⌬ mutation, and C. albicans thr1⌬ mutants were not hypersensitive to FK506. Therefore, despite similarities in S. cerevisiae Fpr1p and C. albicans Rbp1p functions (8), C. albicans Hom3p function may be controlled less by threonine feedback regulation than the S. cerevisiae Hom3p, or C. albicans Hom3p employs a different binding partner to mediate the feedback regulation. It is also possible that C. albicans threonine pathway flux could be controlled by an alternative mechanism, such as phosphatase degradation of aspartyl phosphate, or C. albicans Hom2p may have a weaker affinity for aspartyl phosphate than S. cerevisiae Hom2p.
Intermediate accumulation has been demonstrated to result in toxic effects in various other amino acid biosynthetic mutants. The essential nature of methionine synthase (MET6) in C. albicans (89) and the drug sensitivity of C. neoformans met6 mutants (67) have been attributed to the accumulation of homocysteine, which is structurally similar to homoserine and has been reported to interfere with purine and sterol biosynthesis in Schizosaccharomyces pombe and S. cerevisiae, respectively (19, 31, 66) . Homocysteine editing to homocysteine thiolactone by the yeast methionyl-tRNA synthetase (39) may also be inhibitory to yeast, as is observed in humans (38, 70) . Furthermore, the accumulation of ␤-aspartate semialdehyde is inhibitory in mutants of the homoserine biosynthetic gene encoding homoserine dehydrogenase, HOM6 (4). Indeed, we also observed some deleterious phenotypes for the hom6⌬ mutant such as increased salt and temperature sensitivity compared with the wild type and hom3⌬ mutants, although typically to a lesser extent than that observed for thr1⌬ and thr4⌬ mutants, which could be attributed to ␤-aspartate semialdehyde accumulation. However, since hom6⌬ mutants do not share all of the phenotypes of thr1⌬ and thr4⌬ mutants, and hom6⌬ suppresses thr1⌬ and thr4⌬ mutant-specific phenotypes, we have ruled out a role for ␤-aspartate semialdehyde accumulation in the deleterious phenotypes of thr1⌬ and thr4⌬ mutants.
While phosphohomoserine accumulation may play a role in the toxic phenotypes of thr4⌬ mutants, since thr4⌬ mutants share all of the same phenotypes but phenotypes are generally less deleterious than in thr1⌬ mutants, thr4⌬ mutants may accumulate homoserine, but to a lesser extent than thr1⌬ mutants. When phosphohomoserine levels are high, as seems likely in a thr4⌬ mutant, product inhibition of Thr1p (91) would result in homoserine accumulation, or phosphatases may convert phosphohomoserine back to homoserine. Since phosphoserine phosphatase (Ser2p) catalyzes a similar reaction, the dephosphorylation of phosphoserine to serine (62), Ser2p is a candidate phosphohomoserine phosphatase in S. cerevisiae. What then is the toxic role of homoserine in the cell, and why does it result in such a plethora of phenotypes? We present evidence that homoserine acts as a toxic threonine analog; however, for three of the gene products that metabolize threonine, Cha1p, Ilv1p, or Gly1p, we did not observe any evidence of homoserine inhibition or metabolism. It remains possible that homoserine may act as an allosteric inhibitor of an unknown and/or important yeast gene product. Alternatively, homoserine may be converted to homoserine lactone, similar to the toxicity in mammalian cells caused by conversion of the structurally similar homocysteine to homocysteine thiolactone (40) ; however, we see no evidence of homoserine lactone toxicity in THR1 or thr1⌬ strains (data not shown). A final process in which threonine is a substrate is translation. Homoserine is likely not inhibiting threonine incorporation into proteins via inhibition of the threonyl-tRNA synthetase Ths1p, since overexpression of THS1 did not alleviate homoserine toxicity. Similarly, the lack of suppression of homoserine toxicity by expression of the E. coli threonyl-tRNA synthetase, which does not aminoacylate homoserine (30) , argues against a role for homoserine incorporation into proteins via only Ths1p-mediated aminoacylation. However, since translation is required for homoserine toxicity, homoserine may be misacylated by multiple aminoacyl tRNA synthetases, as is the case for homocysteine (12, 13, (41) (42) (43) (44) . Various homoserinemediated deleterious phenotypes observed for thr1⌬ and thr4⌬ mutants would be consistent with homoserine incorporation into proteins, creating aberrant proteins that are sensitive to various stresses, analogous to effects mediated by the incorporation into protein of toxic amino acid analogs (93, 96) . If homoserine is incorporated into proteins causing misfolding, this would also be consistent with thr1⌬ and thr4⌬ being synthetic lethal with hsp82⌬, an isoform of the chaperone HSP90 important for protein folding (68) , and/or having increased sensitivity to HSP90 inhibitors (57, 97) .
Finally, to elucidate the mechanism of homoserine toxicity, we identified suppressors of homoserine toxicity. Interestingly, most of the suppressor genes encoded functions involved in the ubiquitin pathway, which is important for the regulation or destruction of multiple proteins such as signaling, cell cycle control, membrane, or aberrant proteins (35) . The involvement of the ubiquitin pathway and proteasome in degrading aberrant proteins provides an intriguing explanation for the role of the ubiquitin pathway in homoserine toxicity. Since doa4⌬ and proteasome mutants, which have reduced turnover of ubiquitin-tagged and/or proteasome-bound proteins and thus increased sensitivity to amino acid analogs such as canavanine (3, 32, 59, 80, 90) , actually suppress thr1⌬ homoserine toxicity, any possible misincorporation of homoserine into proteins may not inactivate proteins per se, but may still induce ubiquitin-mediated turnover of homoserine-containing protein, resulting in undesired proteolysis of one or more essential proteins, such as Pma1-114p, which results in cell death.
